James Lehmann, MD
Ophthalmology · San Antonio, TXNPI 1861432114
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,895 of the $162,082 with a category attached, or 76.4%. Rxsight Inc accounts for 76.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2024 at $123,093 and has fallen 95.2% since, to $5,931 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $779.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$124K
- Lensar, Inc.$16K
- Glaukos Corporation$12K
- Johnson & Johnson Surgical Vision, Inc.$5K
- Bausch & Lomb Americas Inc.$2K
- Alcon$629
- plus $2K from 22 others
Across 168 payments — averaging $6433.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$607K
- Rxsight Inc$273K
- Glaukos Corporation$100K
- Avedro Inc.$83K
- AbbVie$18K
What the payments were for
- Consulting fees$20,95013%
- Speaking & faculty fees$123,89576%
- Food & beverage$9,5416%
- Gifts$2220%
- Other$7,4755%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 30 | $124,313 |
| Lensar, Inc. | 25 | $16,121 |
| Glaukos Corporation | 26 | $11,502 |
| Johnson & Johnson Surgical Vision, Inc. | 31 | $5,229 |
| Bausch & Lomb Americas Inc. | 4 | $1,940 |
| Alcon | 24 | $629 |
| AbbVie(2 entities) | 21 | $519 |
| Dompe US, Inc. | 6 | $338 |
| Novartis | 6 | $251 |
| Carl Zeiss Meditec USA, Inc. | 2 | $211 |
| Johnson & Johnson Vision Care, Inc. | 1 | $139 |
| Oyster Point Pharma, Inc. | 2 | $131 |
| NEW World Medical,inc. | 3 | $118 |
| Bausch Health US, LLC | 1 | $102 |
| Sun Pharmaceutical Industries Inc. | 3 | $95 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $91 |
| Eyevance Pharmaceuticals LLC | 4 | $76 |
| Biotissue Holdings Inc. | 2 | $51 |
| Omeros Corporation | 2 | $39 |
| Sight Sciences, Inc. | 2 | $34 |
| ABB Con-cise Optical Group LLC | 1 | $28 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Harrow Eye, LLC | 1 | $19 |
| Optos, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Kala Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$113,830
- RXSIGHT INJECTOR CARTRIDGE$113,830
- RXSIGHT INJECTOR HANDPIECE$113,830
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113,830
- LIGHT ADJUSTABLE LENS (LAL)$113,701
- LENSAR LASER SYSTEM$15,767
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$9,914
- Tecnis IOL$3,845
- Tecnis Symfony IOL$2,250
- Tecnis Multifocal Family of 1-piece IOLS$2,250
- Whitestar Phacoemulsficiation System$2,250
- XIIDRA$1,810
- Whitestar Signature$1,800
- MIEBO$1,700
- KXL System$1,543
- CE-marked KXLA system$1,177
- iDoseTR$518
- Photrexa Viscous and Photrexa$475
- VERITAS Vision System$364
- Tecnis Simplicity$256
How this compares
$162,082 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 208 | $8,867 |
| Difluprednate | 43 | $3,809 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 41 | $2,027 |
| Bromfenac Sodium | 11 | $1,200 |
| ValacyclovirValacyclovir Hcl | 36 | $1,148 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 49 | $1,037 |
| Latanoprost | 42 | $447 |
| Tobramycin | 43 | $192 |
| ErythromycinErythromycin Base | 19 | $175 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Antonio
- Michael SingerSan Antonio$1.8M
- Gregory ParkhurstSan Antonio$185K
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.